Wall Street brokerages expect ZIOPHARM Oncology Inc (NASDAQ:ZIOP) to announce earnings per share (EPS) of ($0.13) for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for ZIOPHARM Oncology’s earnings, with estimates ranging from ($0.16) to ($0.11). ZIOPHARM Oncology reported earnings of ($0.10) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 30%. The business is expected to report its next earnings results on Tuesday, August 8th.

According to Zacks, analysts expect that ZIOPHARM Oncology will report full year earnings of ($0.57) per share for the current fiscal year, with EPS estimates ranging from ($0.75) to ($0.46). For the next financial year, analysts forecast that the firm will post earnings of ($0.63) per share, with EPS estimates ranging from ($0.86) to ($0.45). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that cover ZIOPHARM Oncology.

ZIOPHARM Oncology (NASDAQ:ZIOP) last announced its quarterly earnings results on Monday, May 1st. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by $0.03. The business had revenue of $1.60 million for the quarter, compared to analyst estimates of $1.71 million. The business’s revenue for the quarter was down 18.8% on a year-over-year basis.

ZIOP has been the topic of several recent research reports. HC Wainwright initiated coverage on shares of ZIOPHARM Oncology in a report on Thursday, June 1st. They set a “buy” rating and a $9.50 target price on the stock. ValuEngine upgraded shares of ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a report on Monday, July 17th. Finally, Zacks Investment Research upgraded shares of ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a report on Wednesday, April 26th. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $13.00.

Shares of ZIOPHARM Oncology (NASDAQ ZIOP) opened at 6.08 on Monday. The stock’s 50 day moving average is $5.92 and its 200-day moving average is $6.34. ZIOPHARM Oncology has a 52 week low of $4.45 and a 52 week high of $7.88. The company’s market cap is $794.66 million.

Several institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its position in ZIOPHARM Oncology by 5.7% in the first quarter. Vanguard Group Inc. now owns 7,310,537 shares of the biotechnology company’s stock worth $46,348,000 after buying an additional 396,678 shares in the last quarter. State Street Corp raised its position in ZIOPHARM Oncology by 0.6% in the first quarter. State Street Corp now owns 4,039,207 shares of the biotechnology company’s stock worth $25,607,000 after buying an additional 22,864 shares in the last quarter. Morgan Stanley raised its position in ZIOPHARM Oncology by 19.5% in the first quarter. Morgan Stanley now owns 1,989,175 shares of the biotechnology company’s stock worth $12,610,000 after buying an additional 324,774 shares in the last quarter. Norges Bank acquired a new position in ZIOPHARM Oncology during the fourth quarter worth about $5,556,000. Finally, Geode Capital Management LLC raised its position in ZIOPHARM Oncology by 3.9% in the first quarter. Geode Capital Management LLC now owns 1,016,427 shares of the biotechnology company’s stock worth $6,444,000 after buying an additional 38,173 shares in the last quarter. 38.05% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “Brokerages Expect ZIOPHARM Oncology Inc (NASDAQ:ZIOP) Will Post Earnings of -$0.13 Per Share” was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of US & international copyright law. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/07/24/brokerages-expect-ziopharm-oncology-inc-nasdaqziop-will-post-earnings-of-0-13-per-share.html.

ZIOPHARM Oncology Company Profile

ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.

Get a free copy of the Zacks research report on ZIOPHARM Oncology (ZIOP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ZIOPHARM Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology Inc and related companies with MarketBeat.com's FREE daily email newsletter.